Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole versus perphenazine on serum biochemical factors in bipolar disorder
IRCT20170606034348N6Phase 3Completed
- Sponsor
- Babol University of Medical Sciences
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in bipolar disorder (BD) comparing Aripiprazole + sodium valproate with Perphenazine + sodium valproate (2 arms). Primary endpoints: Fasting blood sugar, Triglycerides and 3 more. Started May 2019; status: completed.
02
Drugs
aripiprazolePerphenazinevalproic acid
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on IRCT20170606034348N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170606034348N6.